News

Reneo Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference

IRVINE, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that the company’s management team will participate at the SVB Securities Global Biopharma Conference. SVB Securities Global Biopharma ConferenceDate: Wednesday,…

Read more

Reneo Pharmaceuticals to Participate in SVB Securities Therapeutics Forum

06/30/2023 IRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that the company’s management team will participate at the SVB Securities Therapeutics Forum. SVB Securities Therapeutics ForumDate: Tuesday, July…

Read more

Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit

October 6, 2023 IRVINE, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate in the Jefferies Biotech CNS/Neuro Summit. Jefferies Biotech CNS/Neuro SummitDate:…

Read more

Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences

November 2, 2023 IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate in the following investor conferences. Jefferies London Healthcare ConferenceDate: Tuesday,…

Read more

Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences

August 29, 2023 IRVINE, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate at the upcoming healthcare investor conferences. Citi BioPharma ConferenceDate: Wednesday,…

Read more

The Lancet Neurology publishes results from Minoryx Therapeutics Phase 2/3 ADVANCE clinical trial of leriglitazone in X-linked Adrenoleukodystrophy

Leriglitazone was well tolerated, and significant benefit was shown through clinically meaningful myelopathy endpoints and reduced progression of cerebral lesions Mataró, Barcelona, Spain, January 20, 2023 – Minoryx Therapeutics (“Minoryx”), a Phase 3 clinical stage biotech company focused on the development of differentiating treatment options in orphan central nervous system (CNS) disorders, today announces that data from its Phase 2/3…

Read more